Weight loss in heart failure is associated with increased mortality only in non-obese patients without diabetes.
Body wasting
Heart failure
Type 2 diabetes mellitus
Weight loss
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
23
01
2019
revised:
15
05
2019
accepted:
12
06
2019
pubmed:
10
8
2019
medline:
28
7
2020
entrez:
10
8
2019
Statut:
ppublish
Résumé
Weight loss (WL) is an independent predictor of mortality in patients with heart failure (HF). Moderate WL is recommended for overweight or obese patients with type 2 diabetes mellitus (DM). The aim of this study was to assess the prognostic impact of body weight reduction on survival in patients with both HF with reduced ejection fraction (HFrEF) and DM. The study comprised patients with HFrEF at the outpatient clinic. WL was defined as a body weight reduction of at least 7.5% during at least 6 months. Clinical features and 1 year mortality were analysed in WL and DM groups. Multivariate regression model was chosen to assess the predictive role of WL in HF patients with and without DM. The analysis regarding obesity before HF was also performed. The study comprised 777 patients with HFrEF. Mean age was 53.2 ± 9.2, 12.0% were women, mean EF was 23.7 ± 6.0 %, and New York Heart Association III or IV class, DM, and WL were found in 60.5%, 33.3%, and 47.1% patients, respectively. WL was more prevalent in diabetic patients, comparing with those without DM (53.7% vs. 43.8%, respectively, 0.01), and was associated with higher 1 year mortality only in non-diabetic group (17.6% for WL vs. 8.2% for non-WL, log-rank 0.001). In the multivariate analysis, WL was associated with a higher risk of 1 year mortality in non-diabetic patients: HR 1.76 (1.05-2.95), 0.03 and only in the subgroup without obesity: HR 2.35 (1.28-4.32), 0.006. In non-diabetic patients with obesity and in diabetic patients regardless of weight status, WL was not associated with worse prognosis (thereof, WL was excluded from the multivariate models). Overall, WL in HFrEF has emerged as a predictor of unfavourable outcomes only in non-obese patients without DM. More importantly, this study has identified that the presence of DM (irrespective of weight status) or the presence of obesity in non-diabetic patients abolished the unfavourable impact of WL on long-term outcomes.
Sections du résumé
BACKGROUND
Weight loss (WL) is an independent predictor of mortality in patients with heart failure (HF). Moderate WL is recommended for overweight or obese patients with type 2 diabetes mellitus (DM). The aim of this study was to assess the prognostic impact of body weight reduction on survival in patients with both HF with reduced ejection fraction (HFrEF) and DM.
METHODS
The study comprised patients with HFrEF at the outpatient clinic. WL was defined as a body weight reduction of at least 7.5% during at least 6 months. Clinical features and 1 year mortality were analysed in WL and DM groups. Multivariate regression model was chosen to assess the predictive role of WL in HF patients with and without DM. The analysis regarding obesity before HF was also performed.
RESULTS
The study comprised 777 patients with HFrEF. Mean age was 53.2 ± 9.2, 12.0% were women, mean EF was 23.7 ± 6.0 %, and New York Heart Association III or IV class, DM, and WL were found in 60.5%, 33.3%, and 47.1% patients, respectively. WL was more prevalent in diabetic patients, comparing with those without DM (53.7% vs. 43.8%, respectively, 0.01), and was associated with higher 1 year mortality only in non-diabetic group (17.6% for WL vs. 8.2% for non-WL, log-rank 0.001). In the multivariate analysis, WL was associated with a higher risk of 1 year mortality in non-diabetic patients: HR 1.76 (1.05-2.95), 0.03 and only in the subgroup without obesity: HR 2.35 (1.28-4.32), 0.006. In non-diabetic patients with obesity and in diabetic patients regardless of weight status, WL was not associated with worse prognosis (thereof, WL was excluded from the multivariate models).
CONCLUSIONS
Overall, WL in HFrEF has emerged as a predictor of unfavourable outcomes only in non-obese patients without DM. More importantly, this study has identified that the presence of DM (irrespective of weight status) or the presence of obesity in non-diabetic patients abolished the unfavourable impact of WL on long-term outcomes.
Identifiants
pubmed: 31397095
doi: 10.1002/jcsm.12471
pmc: PMC6903445
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1307-1315Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 The Authors Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Diabetes Care. 2013 Jan;36 Suppl 1:S11-66
pubmed: 23264422
J Am Coll Cardiol. 2013 Feb 5;61(5):596-7
pubmed: 23273393
J Am Coll Cardiol. 2014 Apr 1;63(12):1123-1133
pubmed: 24491689
Surg Endosc. 2011 Jul;25(7):2338-43
pubmed: 21424205
Eur J Epidemiol. 2014 Nov;29(11):801-12
pubmed: 25354991
J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1307-1315
pubmed: 31397095
Clin Res Cardiol. 2014 Jul;103(7):569-76
pubmed: 24609482
J Card Fail. 2014 Mar;20(3):190-2
pubmed: 24412243
Endocrine. 2013 Jun;43(3):626-34
pubmed: 23179776
Diabetes Care. 2000 Oct;23(10):1499-504
pubmed: 11023143
Lancet. 1997 Apr 12;349(9058):1050-3
pubmed: 9107242
Blood Purif. 2005;23(1):57-63
pubmed: 15627738
Arch Intern Med. 2005 May 9;165(9):1035-40
pubmed: 15883243
Eur J Heart Fail. 2016 Jul;18(7):851-8
pubmed: 27312985
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Heart Fail Rev. 2012 Jan;17(1):81-96
pubmed: 21523383
J Cachexia Sarcopenia Muscle. 2017 Dec;8(6):1081-1083
pubmed: 29098794
J Am Coll Cardiol. 2013 Aug 20;62(8):752-60
pubmed: 23602771
Eur Heart J. 2008 Nov;29(21):2641-50
pubmed: 18819960
Obesity (Silver Spring). 2012 Jul;20(7):1511-8
pubmed: 21959345
Nutr Rev. 2006 Nov;64(11):502-7
pubmed: 17131946
Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):151-156
pubmed: 29852198
Int J Cardiol. 2012 Dec 15;162(1):20-6
pubmed: 22037349
Eur J Heart Fail. 2011 Feb;13(2):200-6
pubmed: 20930001
J Am Coll Cardiol. 2012 Oct 9;60(15):1374-80
pubmed: 22958953
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):142-150
pubmed: 29981771
N Engl J Med. 2013 Jul 11;369(2):145-54
pubmed: 23796131
ESC Heart Fail. 2016 Dec;3(4):227-234
pubmed: 27867523
Circulation. 1992 Jun;85(6):2119-31
pubmed: 1591831
Am J Med. 2016 Sep;129(9):960-965.e1
pubmed: 27154778
Int J Cardiol. 2013 Sep 20;168(1):306-11
pubmed: 23044425
Heart Lung Circ. 2018 Jan;27(1):9-21
pubmed: 28870770
Am J Cardiol. 2010 Nov 15;106(10):1450-5
pubmed: 21059435